Soterix Medical has announced the launch of the MxN-GO EEG system that integrates high-definition transcranial electrical stimulation (HD-tES) with EEG capabilities.
This system is designed to facilitate research applications that require both electrical brain stimulation and activity recording in mobile and natural settings.
Related: Magnus Medical launches neuromod system for treating depressive disorders
The MxN-GO EEG system has a wire-free, lightweight design that simplifies setup and enhances user comfort.
It features 33 stimulation channels and 32 recording channels, offering high precision and targeted application-specific functionality.
The development of the MxN-GO EEG system is a result of a collaboration between Soterix Medical and mBrainTrain, a specialist in mobile EEG solutions.
Together, they have created the tool for conducting mobile hybrid stimulation and EEG studies.
Soterix Medical CEO Dr Abhishek Datta said: “Soterix Medical was founded in 2008 to develop HD-tES as the first transcranial system capable of brain targeting with weak electrical stimulation.
“The MxN-GO EEG solution combines into one product our 16 years of leadership and innovation in High-Definition with the unmatched mobile EEG collection expertise of mBrainTrain.”
“Researchers and clinician-scientists recognise that brain science and medicine advancements increasingly depend on combining brain modulation and recording. Moreover, that reproducibility and rigour absolutely depend on the quality of the equipment used.”
Soterix Medical’s HD-tES is enabled by advanced electrode design, which facilitates the safe and well-tolerated delivery of electrical currents through ‘High-Definition’ electrodes.
The technology also incorporates individualised brain current-flow modelling and in-house targeting algorithms that guide the placement and activation of HD electrodes on the head.
In August 2023, Soterix Medical initiated the Phase II RECOVER-NEURO clinical study to evaluate the effectiveness of combining REMOTE-tDCS with a brain training programme to treat long Covid.
The study was conducted through NYU Langone Health’s home-based remotely supervised tDCS programme, which is accessible to patients across the US.
